ArticleMaterials today. Bio2025
Metal-organic framework-based delivery systems as nanovaccine for enhancing immunity against porcine circovirus type 2.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Immunoregulatory strategies of MOF-based nanodrug delivery systems: Advances in cancer therapy applications and future perspectives.Materials today. Bio · 2026Review
- Advancements in nanomaterial-based adjuvants for animal vaccines.Materials today. Bio · 2026Article
- Pollen-inspired multifunctional nanocarrier for porcine circovirus 2 vaccine delivery.Journal of nanobiotechnology · 2026Article
- Emerging Challenges and Advances in Porcine Circovirus: A Decade in Review.Transboundary and emerging diseases · 2026Review
- Research Progress in the Development of Vaccines AgainstMicroorganisms · 2025Review
- Advances in the Functionalization of Vaccine Delivery Systems: Innovative Strategies and Translational Perspectives.Pharmaceutics · 2025Review
- Nanomaterial Adjuvants for Veterinary Vaccines: Mechanisms and Applications.Research (Washington, D.C.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porcine circovirus type 2 (PCV2) has caused massive economic losses to the global pig farming industry. As emerging nanomaterials, metal-organic frameworks (MOFs) have considerable potential in drug and vaccine delivery because of their unique physicochemical properties. Based on the successful expression and identification of PCV2 antigens (Cap protein), this study exploits MOF platforms to design a nanovaccine delivery system (Cap@ZIF-8-CpG) as a novel subunit vaccine, which effectively enhances the resistance of antigens to denaturation and boosts immune responses against PCV2. Results demonstrate that mice injected with a nanovaccine efficiently incorporating PCV2 antigens (Cap) and an immune enhancer (CpG) elicit robust humoral immune responses. Notably, immunoglobulin G antibody titers are considerably elevated; cytokine secretion is augmented; and the proliferation of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.